GLAXOSMITHKLINE PLC Form 6-K December 02, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 02 December 2016

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Mr S Dingemans	
b)	Position/status	Chief Financial Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
	LEI	5493000HZTVUYLO1D793	
-)	Details of the transaction(s): section to be repeated for (i) ea		
3.			
		Ordinary shares of 25 pence	
a)	Description of the financial instrument	each ('Ordinary Shares')	
	Nature of the transaction	ISIN: GB0009252882	
		Acquisition of Ordinary	
		Shares on 1 December 2016	
		following the exercise of	
		options granted on 30	
b)		October 2013 at the option	
- /		price of £12.47 per Ordinar Share under the Company's	
		ShareSave Plan.	
		$\mathbf{D}_{\mathbf{r}}$	
		Price(s)	Volume(s)
c)	Price(s) and volume(s)	£12.47	216
	Aggregated information		<i>.</i> • ```
d)		n/a (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2016-12-01	
Ð	Place of the transaction	London Stock Exchange	
f)		(XLON)	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised. GlaxoSmithKline plc

(Registrant)

Date: December 02, 2016

By: VICTORIA WHYTE-----

Victoria Whyte

Authorised Signatory for and on

behalf of GlaxoSmithKline plc